BLASOLUTIONINJECTION
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
KIRSTY (water) by Biocon is insulin, including insulin aspart products, is the regulation of glucose metabolism. Approved for glycemic control in adults. First approved in 2025.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KIRSTY is a novel insulin aspart analog injection approved by the FDA for glycemic control in adults with diabetes. It works by stimulating peripheral glucose uptake in skeletal muscle and fat while inhibiting hepatic glucose production, thereby lowering blood glucose levels. The drug also inhibits lipolysis and proteolysis while enhancing protein synthesis.
Launch
Early-stage launch with moderate competitive pressure (30%) presents opportunity for aggressive market penetration and team expansion within the first 24 months.
Mechanism of Action
insulin, including insulin aspart products, is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis,…
Pharmacologic Class:
Insulin Analog
Indications (1)
Clinical Trials (20)
WATER IV PCa (AS Sub-study)
Started Sep 2026
333 enrolled
Localized Prostate Cancer
Water Vapor Ablation for Grade Group 3 Prostate Cancer
Started Jul 2026
120 enrolled
Prostate Cancer
Water Vapor Ablation for Prostate Cancer: Long-Term Registry
Started Jun 2026
2,500 enrolled
Prostate Cancer
Effect of Watermelon on Cardiometabolic Health
Started Apr 2026
22 enrolled
Cardiometabolic Health IndicatorsWhole-body Antioxidant Capacity
GREENWATER 2.0: Reducing Iodinated Contrast Agents in Hospital Wastewater
Started Mar 2026
416 enrolled
Environmental Sustainability in RadiologyIodinated Contrast Agent Recovery
Worked on KIRSTY at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.